Regulations.gov document
Determination That TRINTELLIX (Vortioxetine Hydrobromide) Oral Tablet, EQ 15 Milligram…
Notice · FDA-2017-P-3989 · posted Nov 21, 2017
Key facts
| Document ID | FDA-2017-P-3989-0006 |
|---|---|
| Title | Determination That TRINTELLIX (Vortioxetine Hydrobromide) Oral Tablet, EQ 15 Milligram Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness |
| Document type | Notice |
| Subtype | Determinations |
| Agency | FDA |
| Docket | FDA-2017-P-3989 |
| Posted | Nov 21, 2017 |
| Federal Register citation | 82 FR 55378 |
| FR document number | 2017-25156 |
| Comment period opens | Nov 21, 2017 |
| Effective date | Nov 21, 2017 |
At a glance
- 1–9 Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: